Artiva Biotherapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
ARTV$4.06-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(in thousands, except share data)
| SERIES ACONVERTIBLEPREFERRED STOCK · SERIES BCONVERTIBLEPREFERRED STOCK · COMMON STOCK · ADDITIONALPAID-IN · ACCUMULATEDOTHERCOMPREHENSIVE · ACCUMULATED · TOTALSTOCKHOLDERS’ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| SHARES | AMOUNT | SHARES | AMOUNT | SHARES | AMOUNT | CAPITAL | GAIN (LOSS) | DEFICIT | EQUITY (DEFICIT) | |
| Balance at December 31, 2023 | 3,673,148 | $96,767 | 2,487,237 | $119,646 | 809,758 | $— | $18,988 | $308 | $(181,311) | $(162,015) |
| Conversion of preferred stock into common stock upon completion of IPO | (3,673,148) | (96,767) | (2,487,237) | (119,646) | 6,160,385 | 1 | 216,412 | — | — | 216,413 |
| Exercise of stock options | — | — | — | — | 10,046 | — | 51 | — | — | 51 |
| Issuance of common stock in connection with IPO, net of offering costs | — | — | — | — | 14,920,000 | 2 | 162,323 | — | — | 162,325 |
| Issuance of common shares upon the conversion of SAFE notes | — | — | — | — | 2,391,418 | — | 28,697 | — | — | 28,697 |
| Stock-based compensation expense | — | — | — | — | — | — | 6,980 | — | — | 6,980 |
| Unrealized loss on investments | — | — | — | — | — | — | — | (437) | — | (437) |
| Net loss | — | — | — | — | — | — | — | — | (65,373) | (65,373) |
| Balance at December 31, 2024 | — | $— | — | $— | 24,291,607 | $3 | $433,451 | $(129) | $(246,684) | $186,641 |
| Exercise of stock options | — | — | — | — | 26,834 | — | 138 | — | — | 138 |
| ESPP shares issued | — | — | — | — | 76,916 | — | 233 | — | — | 233 |
| Issuance of common stock in connection with restricted stock units, net | — | — | — | — | 200,193 | — | (230) | — | — | (230) |
| Stock-based compensation expense | — | — | — | — | — | — | 6,821 | — | — | 6,821 |
| Unrealized gain on investments, net | — | — | — | — | — | — | — | 232 | — | 232 |
| Net loss | — | — | — | — | — | — | — | — | (83,865) | (83,865) |
| Balance at December 31, 2025 | — | $— | — | $— | 24,595,550 | $3 | $440,413 | $103 | $(330,549) | $109,970 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.